Roche Roferon-A for chronic hepatitis C labeling recommends 12-month treatment schedule.
Executive Summary
ROCHE ROFERON-A 12-MONTH TREATMENT REGIMEN FOR CHRONIC HEPATITIS C is recommended in product labeling. "Normalization of serum [alamine transaminose] ALT generally occurs within a few weeks after initiation of treatment in responders," labeling states. "Approximately 90% of patients who respond to Roferon-A do so within the first three months of treatment; however, patients responding with a reduction in ALT should complete 12 months of treatment." Schering-Plough's Intron-A labeling recommends that hepatitis C patients complete six months of therapy, but notes that optimal dose and duration are under investigation.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth